Entries |
Document | Title | Date |
20080214631 | USE OF RILUZOLE FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Methods and compositions for the treatment of multiple sclerosis comprising riluzole (6-(trifluoromethoxy)-benzothiazolamine) are disclosed herein. | 09-04-2008 |
20080221178 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof - Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R | 09-11-2008 |
20080234338 | Neurorestoration With R(+) Pramipexole - Formulations and methods of use thereof for restoring neuronal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day. | 09-25-2008 |
20080234339 | Reducing Myocardial Damage and the Incidence of Arrhythmia Arising From Loss, Reduction or Interruption in Coronary Blood Flow - A method and pharmaceutical composition are disclosed for treating, ameliorating and/or preventing one or more myocardial disorders in a mammalian heart caused by a myocardial hypoxic event and/or a loss, reduction or interruption in coronary blood flow such as may happen during or after events such as a heart attack, cardiac surgery including coronary artery bypass graft, or coronary artery or myocardial reperfusion. The myocardial disorders include myocardial arrhythmias, myocardial damage and myocardial cell death, and the subsequent loss of haemodynamic function. The myocardial disorders could be in progress or suspected of being in progress at the time of treatment or could be anticipated disorders being treated prophylactically. The method involves the step of administering an effective amount of the composition. The composition comprises as its active ingredient one or more compounds having myocardial persistent sodium channel blocking activity. A preferred compound is riluzole or a salt or derivative thereof. | 09-25-2008 |
20080249145 | Salts 668 - A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD). | 10-09-2008 |
20080255214 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed. | 10-16-2008 |
20080262053 | Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls) - The invention relates to the use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole, the (+)- or (−)-enantiomer thereof or the pharmacologically acceptable salts thereof for treating moderate to severe Restless Legs Syndrome (RLS). | 10-23-2008 |
20080280960 | Waterbased Bit/Tmad Formulations - Aqueous formulations having a pH of >10 of 1,2-benzoisothiazolin-3-one (BIT) and/or its alkali metal salts and tetramethylolacetylenediurea (TMAD) are outstandingly suitable for protecting industrial materials and products from infection and destruction by microorganisms. | 11-13-2008 |
20080280961 | New amino-alkyl-amide derivatives as CCR3 receptor ligands - The invention relates to a compound of the general formula (I), | 11-13-2008 |
20080287510 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to thiazolylidene containing compounds of formula (I) | 11-20-2008 |
20080293785 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS - The present invention is directed to substituted benzothiazole compounds of formula (I): | 11-27-2008 |
20080319031 | Novel Tyrosine Derivatives - The present invention relates to novel tyrosine derivatives of formula (I), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel tyrosine derivatives of the general formula (I). | 12-25-2008 |
20080319032 | TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS - This invention relates generally to tetrahydrobenzothiazole analogues and tetrahydrobenzooxyzole analogues, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treatment using these compounds. The invention also encompasses pharmaceutically acceptable esters, amides, and salts of such compounds. The invention further provides a method of reducing or delaying apoptosis in a population of cells, comprising contacting the population of cells with a tetrahydrobenzothiazole analogue or a tetrahydrobenzooxyzole analogue, thereby reducing or delaying apoptosis in the population of cells. | 12-25-2008 |
20090012134 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists - Compounds of formula (I): are potent and selective antagonists of the 5-HT | 01-08-2009 |
20090023788 | Treatment of CRTH2-mediated diseases and conditions - The present invention provides indole derivatives that antagonize prostaglandin D | 01-22-2009 |
20090042956 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE - Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 02-12-2009 |
20090048312 | PLANT PATHOGEN RESISTANCE - Azelaic acid or its derivatives or analogs induce a robust and a speedier defense response against pathogens in plants. Azelaic acid treatment alone does not induce many of the known defense-related genes but activates a plant's defense signaling upon pathogen exposure. | 02-19-2009 |
20090054504 | Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same - Modified release pharmaceutical compositions (controlled release, sustained release, and/or extended release) of the R-(+) enantiomer of pramipexole (RPPX) and methods of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 02-26-2009 |
20090105319 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: | 04-23-2009 |
20090124674 | Method for treating congestive heart failure - Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: | 05-14-2009 |
20090137643 | Methods for Inhibiting or Reversing Tau Filament Fibrillization - Methods for inhibiting and/or reversing tau filament formation or fibrillization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or fibrillization. A preferred composition comprises 3-(2-hydroxyethyl )-2-[2-[[3-(2-hydroxyethyl )-5-methoxy-2-benzothiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium. | 05-28-2009 |
20090149518 | PHARMACEUTICAL FOR PROTECTION OF MOTOR NERVE IN PATIENT WITH AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to an agent for protecting a motor nerve of a patient with amyotrophic lateral sclerosis, which comprises a combination of (a) (2R)-2-propyloctanoic acid or a salt thereof and (b) a therapeutic agent for amyotrophic lateral sclerosis such as riluzole. An agent comprising a combination of (a) (2R)-2-propyloctanoic acid which is orally administered once a day in an amount per dose of about 1200 mg and (b) riluzole which is orally administered twice a day in an amount per dose of about 50 mg is useful for protecting a motor nerve in a patient(s) with amyotrophic lateral sclerosis. The agent can also suppress the respiratory disability associated with the progression of the disease condition and improve the survival rate of the patient(s). | 06-11-2009 |
20090170913 | NOVEL MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar | 07-02-2009 |
20090170914 | Cermide Kinase Modulation -
A compound of formula (I) wherein R | 07-02-2009 |
20090197927 | JASMONATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 08-06-2009 |
20090203753 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists - The present invention provides compounds of formula (I) wherein e, R | 08-13-2009 |
20090203754 | ANTI-BACTERIAL DRUG TARGETING OF GENOME MAINTENANCE INTERFACES - Methods for the design and identification of novel antimicrobial compounds are provided, as well as antimicrobial compounds identified using these methods. Pharmaceutical compositions that include these antimicrobial compounds are provided as well. The antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide. In some examples, the prokaryotic single-stranded DNA binding protein is prokaryotic exonuclease I. | 08-13-2009 |
20090221653 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists - The present invention provides compounds of formula (I) wherein the variables are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. | 09-03-2009 |
20090221654 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS - A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions. | 09-03-2009 |
20090239916 | NOVEL DRUG DISCOVERY TARGET AND MEDICINE ACTING ON THE SAME - The present invention provides a pharmaceutical composition comprising as an active ingredient a compound that specifically binds to MFP-2 or a functional fragment thereof and a screening method for the compound; the compound and a pharmaceutical composition comprising the same are highly useful as anti-inflammatory agents and anti-allergic agents. | 09-24-2009 |
20090239917 | Heterocyclic Cycloalkyl Compounds, a Process for their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I): | 09-24-2009 |
20090253762 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 10-08-2009 |
20090270467 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes - The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 10-29-2009 |
20090270468 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 10-29-2009 |
20090275624 | INHIBITORS OF CDC PHOSPHATASES - A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer. | 11-05-2009 |
20090281153 | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. | 11-12-2009 |
20090298897 | Treatment of Inflammatory Disorders With Triazole Compounds - The present invention relates to the use of triazole compounds for reducing inflammation and treating inflammation-associated disorders. | 12-03-2009 |
20090306156 | PHOSPHODIESTERASE 4 INHIBITORS - Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I: | 12-10-2009 |
20090326022 | Biocidal Composition For Leather Tanning - The invention relates to a concentrated solution of TCMTB for the preparation of an emulsion of TCMTB. The concentrated solution comprises (i) 2-(thiocyanomethylthio)-benzothiazole, (ii) an ester of a C | 12-31-2009 |
20100010055 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF - The present invention is directed to compounds of formula (I) | 01-14-2010 |
20100016386 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc | 01-21-2010 |
20100016387 | METHOD OF TREATMENT - Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound. | 01-21-2010 |
20100016388 | Salts of a Selective Beta-2 Andrenoceptor Agonist - A pharmaceutically acceptable salt of 7-[(1R)-2-({2-[3-{[2-(2-Chlorophenyl)ethyl]amino}propyl)thio]ethyl}amino)-1-hydroxyethyl]-4-hydroxy-1,3-benzothia-zol-2(3H)-one provided it is not the ditrifluoroacetate, dihydrobromide or di-acetate salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD). | 01-21-2010 |
20100029732 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone - The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azo-niabicyclo[2.2.2]octane bromide, 3(R)- | 02-04-2010 |
20100048650 | TWO PORE CHANNELS AS A THERAPEUTIC TARGET TO PROTECT AGAINST MYOCARDIAL ISCHEMIA AND AS AN ADJUVANT IN CARDIAC SURGERY - The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel. | 02-25-2010 |
20100063116 | USE OF PRAMIPEXOLE OR A SALT THEREOF FOR THE TREATMENT OF PARKINSON'S DISEASE - The present invention refers to the use of pramipexole, pramipexole hydrochloride, pramipexole dihydrochloride or pramipexole dihydrochloride monohydrate for the manufacture of a medicament for the treatment of early Parkinson's disease by a maintenance, twice daily application. | 03-11-2010 |
20100093813 | Salts 668 - A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD). | 04-15-2010 |
20100099721 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Inhibitors of prolyl endopeptidase of formula 1 | 04-22-2010 |
20100130569 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE COMPRISING NON-ERGOT SELECTIVE D2 RECEPTOR AGONIST AS ACTIVE INGREDIENT - The invention provides a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole which is a non-ergot selective D | 05-27-2010 |
20100130570 | FUNGICIDE N-5-MEMBERED FUSED HETEROARYL-METHYLENE-N-CYCLOALKYL-CARBOXAMIDE DERIVATIVES - The present invention relates N-5-membered, fused, heteroaryl-methylene-N-cycloalkyl-carboxamide derivatives, their thiocarboxamide or N-substituted carboximidamide analogues, all of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents O, S, N—R | 05-27-2010 |
20100168191 | PHARMACEUTICAL FORMULATION COMPRISING PRAMIPEXOLE - The present invention refers to the use of a medicament for the paediatric treatment of RLS and/or Tic Disorder and/or Tourette's Syndrom. | 07-01-2010 |
20100249200 | Novel Compounds 569 - The present invention provides compounds of formula (I) | 09-30-2010 |
20100267781 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: | 10-21-2010 |
20100273840 | WATER-SOLUBLE POLYMER-BASED CANTHARIMIDES AS POTENTIALLY SELECTIVE ANTI-TUMOR AGENTS - A cantharimide compound may include the backbone of formula (1). R | 10-28-2010 |
20100273841 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I):
| 10-28-2010 |
20100273842 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I): | 10-28-2010 |
20100286216 | COMPOSITION HAVING A HIGH OSMOTIC ACTIVITY AND EXHIBITING ANTIMICROBIAL, ANTI-INFLAMMATORY, AND REGENERATIVE EFFECTS - The invention relates to pharmacology and cosmetology, in particular, to a group of medications containing iodine in active form, and may be used to treat septic wounds of different etiology, and also to prevent evolution of skin tissue pathology under the effect of varied injurious factors, including cosmetology. | 11-11-2010 |
20100292284 | Talarazole metabolites - Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO | 11-18-2010 |
20100292285 | METHOXYACRYLATE-BASED FUNGICIDE AND METHODS FOR PREPARING AND USING THE SAME - A pharmaceutical composition of fungicide including at least a compound represented by Formula (I). | 11-18-2010 |
20100298389 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders - The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4′-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof. | 11-25-2010 |
20100305173 | HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES - This invention relates to novel hydroxyethylamino sulfonamides, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor. | 12-02-2010 |
20100324105 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids - Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds. | 12-23-2010 |
20110003870 | METHOD OF TREATMENT OF A NEUROLOGICAL DISORDER - A method of treating neurological conditions, such as Parkinson's Disease and Restless Leg Syndrome, in a mammalian subject is disclosed. The method comprises the administration of a once-a-day controlled release formulation of pramipexole, which formulation provides a consistently ascending PK profile during sleeping hours. | 01-06-2011 |
20110009460 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - Pharmaceutical compositions of dexpramipexole and methods of using such compositions for the treatment of ALS are disclosed. | 01-13-2011 |
20110046191 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β | 02-24-2011 |
20110065760 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF - The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z | 03-17-2011 |
20110086894 | BIOMARKERS FOR THE DIAGNOSIS OF ALS - Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS. | 04-14-2011 |
20110105573 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF - The invention relates to benzimidazole acetic acid compounds which function as antagonists of the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D | 05-05-2011 |
20110130431 | Compounds Which Modulate The CB2 Receptor - Compounds of formula (I) | 06-02-2011 |
20110136879 | COMPOUND - The invention provides compounds of formula (I) | 06-09-2011 |
20110184033 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same - Potent and selective ligands for the dopamine 3 (D | 07-28-2011 |
20110190356 | Compositions and Methods of Using (R)- Pramipexole - Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 08-04-2011 |
20110218222 | NEURORESTORATION WITH R(+) PRAMIPEXOLE - Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day. | 09-08-2011 |
20110224268 | Compositions and methods of using R(+) pramipexole - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 09-15-2011 |
20110237631 | Selective Glycosidase Inhibitors and Uses Thereof - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac. | 09-29-2011 |
20110301210 | USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLEROSIS - The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. | 12-08-2011 |
20110319456 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME - Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like. | 12-29-2011 |
20120015992 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: | 01-19-2012 |
20120022121 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR - Indole derivatives and analogous compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat cancer, metastatic cancer, resistant cancer or multidrug resistant cancer, including inter-alia: prostate cancer, breast cancer, melanoma, colon cancer and bladder cancer. | 01-26-2012 |
20120041041 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY - Compounds of formula (I) in free or salt or solvate form, wherein T has the meaning as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β | 02-16-2012 |
20120095066 | Composition Comprising An Epothilone And Methods For Producing A Composition Comprising An Epothilone - The present invention concerns methods for the production of pharmaceutical formulations of Epothilones suitable for being administered parenterally, such as intravenously. | 04-19-2012 |
20120157504 | New Process - The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound. | 06-21-2012 |
20120184587 | NOVEL PHENOL DERIVATIVE - Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. | 07-19-2012 |
20120214855 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. | 08-23-2012 |
20120220639 | RHODACYANINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR TREATING LEISHMANIASIS - A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R | 08-30-2012 |
20120225915 | Compositions and Methods of Using R(+) Pramipexole - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 09-06-2012 |
20120270912 | Substituted Indolealkanoic Acids - Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis. | 10-25-2012 |
20120283300 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS - This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer. | 11-08-2012 |
20120316206 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more carbamate fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of benthiavalicarb, iprovalicarb, propamocarb, and metam | 12-13-2012 |
20120316207 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 12-13-2012 |
20130040999 | NEW COMPOUNDS FOR ALLEVIATION, PREVENTION OR TREATMENT OF OSTEOPOROSIS, THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides novel compounds of Chemical Formula I, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, a preparation thereof and a composition for the alleviation, prevention or treatment of osteoporosis, comprising thereof in an effective amount, and a method for alleviating, preventing or treating osteoporosis. | 02-14-2013 |
20130102643 | CYTOCHROME P450 INHIBITORS AND USES THEREOF - The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial. | 04-25-2013 |
20130102644 | Prophylactic or Ameliorating Agent for Genetic Diseases - An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower. | 04-25-2013 |
20130116292 | NEURORESTORATION WITH R(+) PRAMIPEXOLE - Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day. | 05-09-2013 |
20130123312 | Compositions and Methods of Using R(+) Pramipexole - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 05-16-2013 |
20130131129 | Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism - An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation. | 05-23-2013 |
20130172394 | USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLEROSIS - The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. | 07-04-2013 |
20130210872 | COMBINATION THERAPY USING RILUZOLE TO ENHANCE TUMOR SENSITIVITY TO IONIZING RADIATION - Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents. | 08-15-2013 |
20130231376 | DEFENSIN-LIKE MOLECULES AS NOVEL ANTIMICROBIAL AGENTS - Disclosed are methods of treating and/or preventing infections in mammals caused by microorganisms, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are the use of such defensin-like molecules for treating and/or preventing infections in mammals; and kits that may include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal. | 09-05-2013 |
20130237572 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS - Topical formulations and method of using the same are provided. The topical formulation comprises a pyrazolylbenzothiazole derivative of the following formula (1) | 09-12-2013 |
20130245080 | BENZOTHIAZOLONE COMPOUND - The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form | 09-19-2013 |
20130245081 | Compositions and Methods for Treating Amyotrophic Lateral Sclerosis - Pharmaceutical compositions of dexpramipexole and methods of using such compositions for the treatment of ALS are disclosed. | 09-19-2013 |
20130253021 | Methods of Making and Using Thioxothiazolidine and Rhodanine Derivatives as HIV-1 and JSP-1 Inhibitors - The present invention provides methods of making and using 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one derivatives having HIV-1 or JSP-1 inhibitory activity. | 09-26-2013 |
20130274300 | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. | 10-17-2013 |
20130289083 | IDO Inhibitors - Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. | 10-31-2013 |
20130310430 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE - Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 11-21-2013 |
20140018401 | CYTOCHROME P450 INHIBITORS AND USES THEREOF - The present invention provides compounds having the general structural formula (I) | 01-16-2014 |
20140031401 | Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same - Modified release pharmaceutical compositions (controlled release, sustained release, and/or extended release) of the R-(+) enantiomer of pramipexole (RPPX) and methods of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 01-30-2014 |
20140142147 | Carbocyanines for G-Quadruplex DNA Stabilization and Telomerase Inhibition - Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer. | 05-22-2014 |
20140187593 | DIAGNOSTIC TEST AND TREATMENT FOR A NEUROLOGICAL DISORDER - Methods and compositions relating to diagnosing and treating a VMAT-2 deficiency disease are described. Provided are methods for screening for, diagnosing or detecting a risk of developing a VMAT-2 deficiency disease comprising detecting the presence of a VMAT-2 variant in a sample of a subject, wherein the presence of the VMAT-2 variant is indicative that the subject has a VMAT-2 deficiency disease or an increased risk of developing a VMAT-2 deficiency disease compared to an individual having wild type VMAT-2. Also provided are methods of treating a VMAT-2 deficiency disease with a dopamine agonist. | 07-03-2014 |
20140315963 | HETEROCYCLIC ACETAMIDE COMPOUND - [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. | 10-23-2014 |
20140329869 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS IN RESPONDERS - A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a subject with amyotrophic lateral sclerosis symptom onset duration of less than about 18 months, a subject with a high level of serum creatinine, a subject with concomitant riluzole administration and combinations thereof. | 11-06-2014 |
20140378515 | IMMUNOSUPPRESSIVE COMPOUNDS - The invention feature series of benzothiazole derivatives as potent immunosuppressive and antiinflammatory agents. Eight compounds 2, 4, 5, 8, 9, 10, 12, and 18 showed potent inhibitory activity on PHA-activated T-cell proliferation. Compounds 2, 4, 8, and 18 were found to have a potent inhibitory activity with IC | 12-25-2014 |
20150018397 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO INCREASED EOSINOPHILS - Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole. | 01-15-2015 |
20150045401 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. | 02-12-2015 |
20150080441 | USE OF RASAGILINE FOR THE TREATMENT OF RESTLESS LEGS SYNDROME - Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 03-19-2015 |
20150094346 | BENZOTHIAZOLONE COMPOUND - The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form | 04-02-2015 |
20150111932 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing neurological degenerative disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Parkinson's disease (PD), restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, sexual dysfunction, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and depression. | 04-23-2015 |
20150133513 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSONS DISEASE - Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release. | 05-14-2015 |
20150291620 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 10-15-2015 |
20150344449 | ANTIBACTERIAL COMPOUNDS - The present invention relates to the following compounds for use in the treatment of a bacterial infection | 12-03-2015 |
20150352082 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES - The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regeneration | 12-10-2015 |
20150353515 | Novel analogs of resveratrol - For the reported resveratrol analogs, the (E)-stilbene core structure is either maintained intact or only slightly modified. We use a different approach and introduced a novel heterocyclic benzothiazolium moiety into the (E)-stilbene core to form a series of novel resveratrol analogs for treating angiogenic- and/or inflammation-related disorders. | 12-10-2015 |
20150361096 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS - The invention relates to heterocyclic amide derivatives of formula (I), | 12-17-2015 |
20150377912 | Method for Determining and Treating Amyotrophic Lateral Sclerosis - The present invention provides a method of determining and treating amyotrophic lateral sclerosis (ALS) in a subject, comprising the following steps: (1) measuring a concentration of an autoantibody against high mobility group box 1 protein (HMGB1) in a biological sample from the subject; and (2) administering an effective amount of ALS-treating drug to the subject whose measured concentration of the autoantibody against HMGB1 is higher than 0.874 μg/ml. | 12-31-2015 |
20160000761 | Formulation comprising benzothiazolone compound - The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt. | 01-07-2016 |
20160000762 | IMPROVING COGNITIVE FUNCTION - Provided herein, inter alia, are compounds useful in improving cognitive function, memory and learning in both healthy and diseased subjects. | 01-07-2016 |
20160022647 | COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 01-28-2016 |
20160030397 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE - Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 02-04-2016 |
20160031858 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES - The present invention relates to novel biologically active compounds, in particular dicarboxylic acid bisamide derivatives of general formula I: | 02-04-2016 |
20160038423 | A PRAMIPEXOLE SUSTAINED RELEASE TABLET FORMULATION AND MANUFACTURING METHOD THEREOF AND USE THEREOF - The present invention relates to a method for preparing the sustained-release tablets via direct compression process, wet granulation process or dry granulation process to obtain the formulations. The present invention also provides a use of the sustained-release tablet formulation of pramipexole in the preparation of pharmaceutical compositions. A sustained release tablet formulation has advantages as follows: breaking out patent monopoly of the innovator preparation, drug dissolution release effects in vitro can be achieved and probably clinical treatment effects can also be accomplished consistent with that of the innovator preparation; abandoning anionic polymers used in the innovator preparation such that making the drug release and absorption not being influenced by the patent body's gastric pH values, in order to avoid the disadvantages of the innovator preparation. Once the tablet formulation is authorized to marketing, the price will be lowered, capable of bringing out effective medical treatment and economical spending for patients. | 02-11-2016 |
20160046591 | INHIBITION OF IL-2 PRODUCTION - An object is to find a substance which inhibits IL-2 production.
| 02-18-2016 |
20160075670 | BENZOTHIAZOLONE COMPOUND - The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form | 03-17-2016 |
20160102066 | BENZOTHIAZOLE DERIVATIVE AND ANTI-TUMOR USE THEREOF - The present invention relates to a benzothiazole derivative of formula 1 or a pharmaceutically acceptable salt thereof and a process for preparation thereof. The present invention also relates to a pharmaceutical composition comprising the compounds and the use of the compounds in the preparation of an anti-tumor medicament. | 04-14-2016 |
20160106651 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. | 04-21-2016 |
20160113908 | Transdermal Therapeutic System for Extended Dosing of Pramipexole in Treating Neurological Disorders - This disclosure relates to a transdermal therapeutic system (TTS) containing pramipexole or related compounds and methods of making the system as well as its use in administering such compounds as a single dose over an extended period, for example, one week. The system comprises an acrylic-based or silicone-based matrix layer containing pramipexole at concentrations of at least about 5 wt. % of the matrix, which is resistant to crystallizing and discoloration of the active ingredient even when stored over long periods. | 04-28-2016 |
20160115160 | 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof - Provided are a compound of formula I which can be used as a drug against small RNA virus infections, and optical isomers, pharmaceutically acceptable salts, solvates or hydrates thereof. Also provided are the preparation method of the compound, the method for using the compound for treating bacterial infections and the use of the compound in the preparation of a drug for preventing and/or treating viral diseases caused by small RNA viruses. | 04-28-2016 |
20160120851 | BENZOTHIAZOLE DERIVATIVES AND A USE THEREOF FOR THE TREATMENT OF CANCER - Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: | 05-05-2016 |
20160158206 | Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism - An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation. | 06-09-2016 |
20160193186 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC URTICARIA | 07-07-2016 |
20160193187 | COMPOSITIONS AND METHODS FOR TREATING PLASMA CELL DISORDERS AND B-CELL PROLYMPHOCYTIC DISORDERS | 07-07-2016 |
20160194337 | GLYCOSIDASE INHIBITORS AND USES THEREOF | 07-07-2016 |
20170231966 | INHIBITION OF IL-2 PRODUCTION | 08-17-2017 |
20190142766 | USE OF RASAGILINE FOR THE TREATMENT OF RESTLESS LEGS SYNDROME | 05-16-2019 |
20190142809 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | 05-16-2019 |